ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KROS / options
ELDN (37) SIGA (68) SLGL (48) NATR (64) ⌘ Pro Terminal →

Keros Therapeutics Inc. (KROS) Options Positioning, Max Pain & Unusual Sweeps

$10.83 +0.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.82

Keros Therapeutics Inc. (KROS) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $213.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KROS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KROS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Keros Therapeutics Inc. (NASDAQ: KROS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.83 (+0.65% 1D, market cap $213.3M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, KROS ranks #130 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KROS compare to ELDN and SIGA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KROS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, ELDN (Eledon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $212.9M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $212.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KROS?
▼

Per KROS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001664710), Keros Therapeutics Inc. generated $244.1M in revenue (+6775.0% YoY), $87.0M in net income, and $106.0M in free cash flow against $338.0M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.82 (-0.07%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 43.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C · Rk C
Cash (19)Whales (6)SEC (16)Macro (10)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$24 Bull$11 Base$9 Bear
📬 FREE KROS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KROS)Realized 20D OHLCV Swing Band: ±9.8%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY KROS SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 43.4% FCF Margin ($106.0M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 4.31 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
72
Grade B$11.05+1.2% Next Q
Q2 (-2Q)
69
Grade B-$11.18+3.8% Next Q
Q3 (-1Q)
67
Grade B-$11.61-6.7% Next Q
Current
64
Grade C$10.83+1.1% Hist 90D α
Trajectory: B (72) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the KROS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, KROS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($11.25) or 200D SMA ($11.94) invalidates the momentum regime and cuts Target Base ($11.12) toward Bear Floor ($8.67).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KROS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KROS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±9.8%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (KROS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for KROS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating KROS & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on KROS
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KROS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.99%🛡️ HOLDING TREND SUPPORT
2026-11-04O $11.04H $11.04L $10.76C $10.83VOL 139.2K
RES: $12.57SUP: $10.68SMA50: $11.25SMA200: $11.94
$15.95$14.25$12.56$10.86$9.16RES $12.57SUP $10.68$10.832026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KROS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KROS Butterfly Map → + Track KROS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6775.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KROS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KROS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KROS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KROS)

Health Care Rank #130 of 1015 ⚔️ ELDN vs KROS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KROS vs. ELDN, SIGA, SLGL, NATR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Keros Therapeutics Inc. (KROS) ranks #130 by composite RQD confidence (64/100, grade C) and #560 by equity capitalization ($213.3M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with KROS at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KROS ACTIVE
Keros Therapeutics Inc.
C 64/100 — — 85.0% +0.65% $213.3M Benchmark Subject
ELDN
Eledon Pharmaceuticals Inc.
D- 37/100 — — -35.0% 0.00% $212.9M /eldn-vs-kros →
SIGA
SIGA Technologies Inc.
C+ 68/100 9.8x 68.6% 42.7% +5.42% $212.0M /siga-vs-kros →
SLGL
Sol-Gel Technologies Ltd.
D 48/100 — — -35.0% -2.86% $215.1M /slgl-vs-kros →
NATR
Nature's Sunshine Products Inc.
C 64/100 11.1x 72.4% 28.9% +0.42% $211.5M /natr-vs-kros →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001664710 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Keros Therapeutics Inc. (KROS) reported GAAP revenue of $244.1M (+6775.0% vs. FY2024 revenue of $3.5M , and +161529.8% cumulative change since FY2023) , GAAP net income of $87.0M, operating cash flow of $107.5M, and free cash flow of $106.0M (+165.1% YoY). On the balance sheet, KROS closed FY2025 with $338.0M in total assets against $0 in total debt (Altman Z-Score: 4.31, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $244.1M $87.0M $107.5M $106.0M $338.0M —
FY2024 (FY) 2024-12-31 $3.5M -$187.4M -$160.9M -$162.8M $615.9M —
FY2023 (FY) 2023-12-31 $151.0K -$153.0M -$124.5M -$124.5M — —

3. KROS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KROS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Keros Therapeutics Inc. (NASDAQ: KROS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.83 (+0.65% 1D, market cap $213.3M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, KROS ranks #130 in composite RQD confidence.

How does KROS compare to ELDN and SIGA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KROS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, ELDN (Eledon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $212.9M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $212.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KROS?

Per KROS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001664710), Keros Therapeutics Inc. generated $244.1M in revenue (+6775.0% YoY), $87.0M in net income, and $106.0M in free cash flow against $338.0M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KROS trading relative to its 50-day, 200-day, and 52-week technical levels?

KROS last traded at $10.83 (+0.65% on volume of 105,970 shares), positioning the stock -3.73% below its 50-day simple moving average ($11.25) and -9.30% below its 200-day simple moving average ($11.94). Across its 52-week range of $9.69 to $22.55, KROS sits at the 8.9% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($9.77 to $11.89).

Direct Sub-Reports: KROS RQD Cockpit KROS 12M Forecast KROS Earnings & Move KROS Dividends & DRIP KROS Insiders & 13F KROS Whale Options KROS Profit Sankey KROS News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

KROS — Keros Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Keros Therapeutics Inc. (KROS) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $10.83 (+0.65% 1D, market capitalization $213.3M).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of —, operating margin of 27.7%, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.31, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Keros Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, the company is associated with a Phase II rinvatercept trial in DMD and a milestone payment. —: the specific products sold, customer base, and revenue model beyond these references.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Keros Therapeutics Inc. (KROS) reported $244.1M in annual revenue (up from $3.5M in FY2024, +6775.0% YoY) and $87.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($151.0K revenue, -$153.0M net income) through FY2025, KROS scaled operating cash flow to $107.5M and free cash flow to $106.0M, backed by $338.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 64/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $9.69 – $22.55 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against 27.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — Investors should watch dependence on the rinvatercept DMD program and the timing of the 2027 data readout referenced in the news wire, as these are the only catalysts named in the sources.

  • Key Question #1: Can KROS sustain or expand its 27.7% operating margin and 85.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $244.1M and free cash flow of $106.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KROS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KROS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Keros Therapeutics Inc. (KROS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KROS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KROS Bull vs. Bear Conversation Board — What's Your Call at $10.83?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KROS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KROS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $12.92 (+17.0%)
📌 Pinned Debate

FY 2025 turned to $87.0M net income with an 85% ROIC and a Piotroski F-Score of 8/9, supporting a strong fundamental profile.

The street is overcomplicating Keros Therapeutics Inc. (KROS). FY 2025 turned to $87.0M net income with an 85% ROIC and a Piotroski F-Score of 8/9, supporting a strong fundamental profile.. With an RQD score of 64/100 (C) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $11.92.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 6/20 institutional whale-flow stock at $11.04 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $8.83 (-20.0%)
Spot @ $11.04

Institutional flow scores only 6/20 and FCF yield is 0%, while cash fell from $559.9M to $287.4M.

Institutional flow scores only 6/20 and FCF yield is 0%, while cash fell from $559.9M to $287.4M.. Look at the math on KROS: paying current EV/EBITDA multiples for 85.0% ROIC and 27.7% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $9.72 before getting long.

LIVE TAPE